Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AYTU vs EOLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EOLS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)
EOLS Overall Winner
6-Pillar Tally: AYTU 3 – 3 EOLS
Matrix Metrics: AYTU 5 – 5 EOLS
As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas EOLS carries 41.8/100 (SELL) at $6.69 (24.9x Forward P/E, -5.4% operating margin).
- Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. EOLS 41.8/100 SELL), EOLS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -14.4% operating margin) and revenue trajectory (+13.0% vs. +6.4% YoY).
- Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AYTU vs EOLS
AYTU
AYTU BioPharma, Inc. Common Stock
$1.81
+1.69% 1D
Market Cap
$19.6M
TTM Revenue
$58M
Forward P/E
9.2x
Beta / 30D Vol
0.65β · 35% Vol
Unified Composite Score
48.9
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
EOLS
Head-to-Head Winner
Evolus, Inc. Common Stock
$6.69
-3.88% 1D
Market Cap
$475.2M
TTM Revenue
$325M
Forward P/E
24.9x
Beta / 30D Vol
1.31β · 60% Vol
Unified Composite Score
41.8
SELL
Tech 29.0
Fund 54.0
Flow 72.0
Mom 39.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (AYTU 3 – 3 EOLS)
1. Valuation Multiples
AYTU
Forward P/E
9.2x
24.9x
Trailing P/E
9.2x
14.9x
PEG Ratio
N/M
N/M
EV / Revenue
0.3x
1.8x
2. Growth & Scale
EOLS
Revenue Growth (YoY)
+6.4%
+13.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$58M
$325M
Market Cap
$19.6M
$475.2M
3. Profitability & Quality
EOLS
Gross Margin
64.0%
66.1%
Operating Margin
-14.4%
-5.4%
Net Profit Margin
-24.8%
-9.6%
Return on Equity (ROE)
-52.5%
-18729.6%
4. Balance Sheet & Cash Flow
AYTU
Cash Generation (TTM)
-$1.4M
-$8.8M
Cash Flow Margin
-2.4%
-2.7%
Net Cash / Leverage
$4.9M Net Cash
$124M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EOLS
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
46.4% (4th %ile)
Put/Call OI Skew
N/A
0.07x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
AYTU
OpEx & R&D Intensity
78.4% of Rev ($45M)
71.5% of Rev ($233M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AYTU (5) vs EOLS (5)| Institutional Metric | AYTU | EOLS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $19.6M | $475.2M | EOLS | |
| Trailing P/E Ratio | 9.2x | 14.9x | AYTU | |
| Forward P/E Ratio | 9.2x | 24.9x | AYTU | |
| Revenue Growth (YoY) | +6.4% | +13.0% | EOLS | |
| Operating Margin (TTM) | -14.4% | -5.4% | EOLS | |
| Net Profit Margin | -24.8% | -9.6% | EOLS | |
| Return on Equity (ROE) | -52.5% | -18729.6% | AYTU | |
| 52-Week Range Position | 5% ($2–$3) | 52% ($4–$9) | EOLS | |
| Beta / 30D Volatility | 0.65β · 35% Vol | 1.31β · 60% Vol | AYTU | |
| Unified Institutional Score | 48.9 / 100 (HOLD) | 41.8 / 100 (SELL) | AYTU | |
| Trailing 12M Revenue (USD) | $58M | $325M | Scale | |
| Gross Profit Margin (TTM) | 64.0% | 66.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | N/M PEG · 1.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$1.4M ($4.9M Net Cash) | -$8.8M ($124M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EOLS +5.5 pp
3M Horizon
EOLS +5.09 pp
6M Horizon
EOLS +15.64 pp
1Y Horizon
EOLS +2.91 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AYTU Revenue | EOLS Revenue | AYTU Op. Margin | EOLS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $30M | -230.1% | -283.3% | AYTU |
| FY2020 | $30M | $60M | -76.5% | -270.7% | AYTU |
| FY2021 | $70M | $100M | -89.7% | -44.6% | EOLS |
| FY2022 | $100M | $150M | -113.7% | -44.0% | EOLS |
| FY2023 | $110M | $200M | -15.9% | -24.4% | AYTU |
| FY2024 | $70M | $270M | -2.4% | -12.9% | AYTU |
| FY2025 | $70M | $300M | -11.8% | -11.0% | EOLS |
| FY2026 | $60M | N/A | -14.4% | N/A | AYTU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AYTU
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EOLS
CONSOLIDATION
Current IV
46.4%
IV Percentile
4th %ile
Put/Call OI Skew
0.07x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact EOLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AYTU Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
78.4% of Rev ($45M)
90D Engineering Disclosures
0 Published
EOLS Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
71.5% of Rev ($233M)
90D Engineering Disclosures
0 Published
Investor FAQ AYTU vs EOLS Key Questions & Quantitative Answers
As of Nov 16, 2026, Evolus, Inc. (EOLS) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas EOLS carries 41.8/100 (SELL) at $6.69 (24.9x Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. EOLS 41.8/100 SELL), EOLS captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-5.4% vs. -14.4% operating margin) and revenue trajectory (+13.0% vs. +6.4% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile EOLS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EOLS leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with EOLS at +13.0% YoY revenue growth and +0.0% YoY earnings growth on $325M TTM revenue (66.1% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while EOLS shifted +900.0%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus 71.5% of Rev ($233M) (0 disclosures) for EOLS.
AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas EOLS trades at 24.9x Forward P/E, 14.9x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-2.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus EOLS (-18729.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, EOLS carries 46.4% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EOLS vs AYTU · Reverse Pair
EOLS vs SLDB
· Sector Peer
EOLS vs ANAB
· Sector Peer
EOLS vs COLL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking